BRIEF-ORIC Pharmaceuticals Presents Preclinical Data To Support The Potential Of Oric-944 As A Best-In-Class PRC2 Inhibitor For The Treatment Of Prostate Cancer

Reuters
Yesterday
BRIEF-ORIC Pharmaceuticals Presents Preclinical Data To Support The Potential Of Oric-944 As A Best-In-Class PRC2 Inhibitor For The Treatment Of Prostate Cancer

April 28 (Reuters) - Oric Pharmaceuticals Inc ORIC.O:

  • ORIC® PHARMACEUTICALS PRESENTS PRECLINICAL DATA TO SUPPORT THE POTENTIAL OF ORIC-944 AS A BEST-IN-CLASS PRC2 INHIBITOR FOR THE TREATMENT OF PROSTATE CANCER AT THE 2025 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING

Source text: ID:nGNXrDQzn

Further company coverage: ORIC.O

(Reuters.Briefs@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10